Quest Diagnostics Inc Stock Price, News & Analysis

Quest Diagnostics (NYSE: DGX) has entered into an all-cash agreement to acquire Mercy's outreach laboratory services business. This transaction, expected to complete in Q2 2021, aims to enhance access to innovative lab services across Arkansas, Kansas, Missouri, and Oklahoma. Mercy will retain its hospital laboratories for inpatient care, while Quest will integrate outreach tests into its network. The partnership prioritizes affordable patient care, leveraging Quest's advanced testing capabilities, patient service centers, and competitive pricing.

Genalyte and Sonora Quest Laboratories have announced a strategic partnership with Cigna Medicare Arizona to enhance health outcomes using predictive analytics. This collaboration aims to reduce costs while improving care for patients enrolled in Cigna's Medicare Advantage plans. Through Genalyte's analytic models, healthcare providers can identify patients needing clinical oversight, enabling timely interventions. Cigna's goal is to leverage advanced analytics to foster informed decision-making, ultimately driving better health outcomes for customers.

Quest Diagnostics (NYSE: DGX) has launched a new COVID-19 semi-quantitative serology test. This service provides insights into an individual's immune response from prior SARS-CoV-2 infections or vaccinations, offering both positive/negative results and numerical data on antibody levels. With about 40% of COVID-19 cases being asymptomatic, this test can identify antibodies two weeks post-infection. The testing aims to enhance public health monitoring by contributing to herd immunity research. It's currently available through Quest's network of over 2,200 patient service centers in the U.S.

Quest Diagnostics (NYSE: DGX) announced leadership changes in its Board of Directors. Dr. Daniel C. Stanzione will step down as Lead Independent Director and not seek reelection in May 2021, after serving since 1997. Timothy M. Ring will succeed him, bringing valuable experience from his time as former Chairman and CEO of C.R. Bard. Vicky Gregg will take over as Chair of the Compensation Committee. Stanzione expressed optimism for the company's future, highlighting the strength of the leadership team.

GRAIL has partnered with Quest Diagnostics (NYSE: DGX) to provide phlebotomy services for its Galleri multi-cancer early detection blood test. This partnership leverages Quest's extensive network, including 2,200 patient service centers and 5,000 mobile phlebotomists, to facilitate blood collection across the U.S. Galleri can detect over 50 types of cancers, with a low false positive rate of less than 1%. Scheduled for introduction in Q2 2021, Galleri will be available through healthcare partners and aims to transform cancer diagnostics and outcomes.

Quest Diagnostics (NYSE: DGX) is set to present at Citi's 2021 Healthcare Services Conference on February 24, 2021, at 1:30 p.m. Eastern Time. Mark Guinan, Executive Vice President & CFO, will discuss the company's vision and capital strategies. The presentation will be available via live webcast and archived for later viewing until March 26, 2021, on their investor relations page. Quest Diagnostics provides critical diagnostic insights, aiding in public health responses, including COVID-19 testing.

Quest Diagnostics (NYSE: DGX) has renewed its strategic partnership with EmblemHealth, one of the largest non-profit health insurers in the U.S., serving over 3 million members. This renewed agreement ensures Quest remains the sole national laboratory for EmblemHealth's HIP products throughout 2021, enhancing patient care through improved diagnostic testing. CEO Steve Rusckowski emphasized the commitment to reducing care costs and improving member outcomes. Quest will also collaborate with AdvantageCare Physicians, supporting nine patient service centers.

Quest Diagnostics (NYSE: DGX) will host a virtual Investor Day on March 11, 2021, at 9:00 a.m. ET for institutional investors and financial analysts. Key executives, including CEO Steve Rusckowski and CFO Mark Guinan, will discuss the U.S. laboratory market and the company's growth strategies. Participants can register for the live webcast here. An archived version will be available later on the Quest Diagnostics Investor Relations website.